These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21195307)

  • 21. Hematopoietic stem cell transplantation in multiple myeloma.
    Pant S; Copelan EA
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):877-85. PubMed ID: 17640590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)].
    Lokhorst H; Huijgens PC; Raymakers R; Bos GM; Vellenga E; Wijermans PW; Sonneveld P;
    Ned Tijdschr Geneeskd; 2005 Apr; 149(15):808-13. PubMed ID: 15850271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
    Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
    Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Stem cell transplantation in multiple myeloma].
    Fukuda S; Sunami K; Sezaki T
    Gan To Kagaku Ryoho; 1999 Sep; 26(10):1407-14. PubMed ID: 10500527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving indications for hematopoietic stem cell transplantation in multiple myeloma and other plasma cell disorders.
    Tricot G; Zangari M; Sorasio R; Bruno B
    Cancer Treat Res; 2009; 144():317-55. PubMed ID: 19779883
    [No Abstract]   [Full Text] [Related]  

  • 27. [The importance of autologous transplantation in multiple myeloma].
    Pour L; Hájek R; Adam Z; Krejcí M; Vorlícek J
    Vnitr Lek; 2009 Sep; 55(9):767-72. PubMed ID: 19785373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.
    Harousseau JL; Attal M; Divine M; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M; Abgrall JF
    Stem Cells; 1995 Aug; 13 Suppl 2():132-9. PubMed ID: 8520502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bortezomib in multiple myeloma patients after allogeneic stem cell transplantation].
    Vokurka S
    Klin Onkol; 2010; 23(4):242-4. PubMed ID: 20806822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
    Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P;
    Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials.
    Markman M
    Gynecol Oncol; 2007 Aug; 106(2):279-81. PubMed ID: 17662376
    [No Abstract]   [Full Text] [Related]  

  • 32. In focus: (166) Ho-DOTMP in the pretransplant treatment of multiple myeloma.
    Clapp K
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):753-4. PubMed ID: 16170894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of multiple myeloma: the changing landscape.
    Reece DE
    Blood Rev; 2007 Nov; 21(6):301-14. PubMed ID: 17761373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [High-dosage chemotherapy with support of autologous haematopoietic cells in the treatment of multiple myeloma--review of contemporary possibilities].
    Rácil Z; Adam Z; Hájek R; Tomíska M; Krejcí M; Krivanová A; Höklová J; Doubek M; Mayer J; Vorlícek J
    Vnitr Lek; 2001 Feb; 47(2):92-8. PubMed ID: 15635853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.
    Manochakian R; Miller KC; Chanan-Khan AA
    Oncologist; 2007 Aug; 12(8):978-90. PubMed ID: 17766658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allografting or autografting for myeloma.
    van Rhee F; Crowley J; Barlogie B
    N Engl J Med; 2007 Jun; 356(25):2646-8; author reply 2646-8. PubMed ID: 17582078
    [No Abstract]   [Full Text] [Related]  

  • 38. Stem-cell transplantation for multiple myeloma in the era of novel drugs.
    Bensinger W
    J Clin Oncol; 2008 Jan; 26(3):480-92. PubMed ID: 18056678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of new treatment approaches in defining treatment goals in multiple myeloma--the ultimate goal is extended survival.
    Durie BG
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S18-23. PubMed ID: 20472184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New treatment strategies for multiple myeloma].
    Ozaki S
    Rinsho Ketsueki; 2009 Oct; 50(10):1506-17. PubMed ID: 19915360
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.